Registry collecting information on people with cardiac angiosarcoma, a rare heart cancer
Collects health records of people with a rare, aggressive cancer of the heart's blood vessels.
Plain-language title generated from the registry record
Registry title: Cardiac Angiosarcoma International Registry
Key facts
- Where
- Yerevan, ArmeniaSee the site
Where in Armenia
- Yeolyan Hematology and Oncology CenterYerevan, ArmeniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Immune Oncology Research Institute
- Trial code
- NCT06715579
- Record updated
- 18 February 2026
- Original description
Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors arising from the endothelial cells (ECs) lining the blood vessels of the heart and account for approximately 25%-30% of all primary cardiac malignancies. It is considered to be the most fatal and aggressive primary cardiac malignancy. This international registry aims to establish a large multicenter database of patients with cardiac angiosarcoma. Our objectives are:Read full original descriptionShow less
Cardiac Angiosarcoma International Registry
Primary cardiac angiosarcomas (PCA) are highly aggressive malignant heart tumors arising from the endothelial cells (ECs) lining the blood vessels of the heart and account for approximately 25%-30% of all primary cardiac malignancies. It is considered to be the most fatal and aggressive primary cardiac malignancy. This international registry aims to establish a large multicenter database of patients with cardiac angiosarcoma. Our objectives are:
1. Collect clinical data, including demographics, medical history, treatments, and outcomes, to build a comprehensive database. 2. Analyze data to evaluate and identify genetic, environmental, or lifestyle risk factors for cardiac angiosarcoma. 3. Evaluate the effectiveness of various treatments (surgery, chemotherapy, immunotherapy, radiation) to inform best practices. 4. Develop evidence-based guidelines and recommendations for prevention, diagnosis, treatment, and management based on registry data.
Inclusion: Histological Confirmation: A confirmed diagnosis of cardiac angiosarcoma through histopathological examination, including subtypes such as hemangiosarcoma and epithelioid hemangiosarcoma; Diagnosis Timing: Eligible patients must have been diagnosed between January 2015 and January 2035; Geographical Representation: Participants should be from diverse geographical locations to ensure a comprehensive understanding of the disease across different populations; Treatment Status: Patients who have received any treatment (surgery, chemotherapy, immunotherapy or radiation) for cardiac angiosarcoma may be included to evaluate treatment outcomes; Informed Consent: For prospective patients, informed consent must be obtained before they are included in the registry; Clinical Data Availability: Relevant clinical data, including demographics, tumor characteristics (size, location), treatment regimens, and outcomes, must be available for analysis; Follow-Up Willingness: Participants should be willing to undergo follow-up assessments as part of the registry's data collection efforts.
Exclusion: Cases where cardiac involvement is secondary to another primary malignancy; Patients who decline to provide informed consent.